Physician profile
Khalid Aziz
NPI 1538165055
$10,392.00
in general payments reported to CMS, 2019-2025
28 companies · $1,084 in 2025
The $1,084 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,087 · 2020: $1,343 · 2021: $1,915 · 2022: $1,343 · 2023: $1,250 · 2024: $1,371 · 2025: $1,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,704.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,948.73 | 2019-2025 | Linzess, Viberzi, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,176.77 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $1,068.54 | 2020-2023 | |
| Phathom Pharmaceuticals, INC. | $998.74 | 2023-2025 | Voquezna |
| Qol Medical, LLC | $856.62 | 2019-2024 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $645.12 | 2019-2025 | Entyvio |
| Redhill Biopharma INC. | $402.21 | 2020-2022 | |
| Gilead Sciences, INC. | $378.61 | 2019-2025 | |
| Pfizer INC. | $330.88 | 2019-2023 | |
| Concordia Pharmaceuticals INC. | $251.72 | 2019 | |
| Allergan, INC. | $241.85 | 2019 | |
| Ardelyx, INC. | $223.33 | 2022-2024 | Ibsrela |
| Romark Laboratories, Lc | $204.57 | 2019-2020 | |
| Genzyme Corporation | $191.10 | 2022-2024 | |
| Intercept Pharmaceuticals, INC. | $172.27 | 2020-2024 | Ocaliva |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $162.80 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $158.00 | 2023 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $152.37 | 2024 | Bylvay |
| Celgene Corporation | $147.15 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $144.44 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $97.42 | 2024-2025 | Zenpep |
| Ucb, INC. | $93.82 | 2019 | |
| Ironwood Pharmaceuticals, INC | $90.08 | 2019-2020 | |
| Pentax of America, INC. | $79.69 | 2022 | |
| Boston Scientific Corporation | $60.88 | 2019 | |
| Alfasigma USA, INC. | $46.34 | 2020-2021 | |
| Janssen Biotech, INC. | $36.46 | 2020-2021 | |
| Lilly USA, LLC | $31.49 | 2025 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Aziz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.